Phage therapy Market Outlook 2026–2038: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief
What This Brief Covers
This Meticulous Next™ brief examines phage therapy, the use of bacteriophages, viruses that infect bacteria, to treat infections that no longer respond to antibiotics. It tests how fast clinical trials and compassionate use move into approved products, and which participants capture value among phage developers, pharmaceutical partners, manufacturers and hospitals.
The first pivotal programme is now defined. In January 2026 Armata Pharmaceuticals reported that the FDA Center for Biologics Evaluation and Research reviewed its End-of-Phase 2 submission for AP-SA02, an intravenous phage cocktail for complicated Staphylococcus aureus bacteremia, and gave recommendations for a phase 3 superiority trial against standard-of-care antibiotics with clinical response and healthcare impact as primary endpoints. The programme carries a USD 26.2 million award from the US Department of Defense and a Qualified Infectious Disease Product designation, which can add five years of market exclusivity. The conclusion is that a phage product has a defined route to a pivotal trial, and the outcome of that trial sets the pace for the whole field.
Financing is the constraint. Armata reported cash of USD 14.1 million at the end of 2025, a net loss of USD 173.8 million for the year of which USD 105.8 million in the fourth quarter was a non-cash charge tied to a convertible loan, and an auditor paragraph expressing substantial doubt about continuing as a going concern. Innoviva, the largest shareholder, extended debt maturities to 1 June 2027 in January 2026, and the phase 3 start expected in the second half of 2026 depends on funding. The conclusion is that clinical progress in phage therapy depends on a small number of strategic backers, and the cost of a pivotal trial exceeds what small developers hold.
The wider field is broadening. TechnoPhage reported that its phase 2b trial of TP-102 in diabetic foot ulcers showed safety and tolerability, and Locus Biosciences uses engineered phages made on robotic platforms, holds a USD 3.3 million contract from the National Institute of Allergy and Infectious Diseases and partners with Viatris on ophthalmic uses. Antibiotic resistance causes roughly 5 million deaths a year, and the specificity of phages to bacterial strains, manufacturing standards and unclear approval pathways are named as the main barriers. The conclusion is that phage therapy is likely to complement antibiotics in resistant infections first, and approvals depend on trial design that handles strain specificity.
The brief treats phage therapy as an emerging signal with a twelve year horizon to 2038. It identifies which applications, regions and operators scale first and what each means for developers, pharmaceutical partners, manufacturers and hospitals. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.
| Parameter | Details |
|---|---|
| Forward horizon | 2026–2038 (12 years) |
| Emerging force | Phage therapy: clinical trials and compassionate use targeting resistant infections |
| Technology readiness | One phase 3 programme planned after FDA end-of-phase 2 review; phase 2 results in several indications; no approved phage product in the United States |
| Indicative market size & forecast | The phage therapy market, covering clinical-stage phage therapeutics, compassionate use programmes, phage production and testing services for resistant bacterial infections, is valued at USD 0.1–0.2 billion in 2026 and is projected to reach USD 2.33–4.66 billion by 2038, at a CAGR of 30% |
| Mainstream inflection | ~2034, when the first phage products are approved and used in routine care for resistant infections |
| Signal strength | FDA recommendations for a phase 3 trial, a USD 26.2 million US Department of Defense award and a Qualified Infectious Disease Product designation |
| Primary beneficiaries | Developers with pivotal trial data; strategic backers; manufacturers of phage products |
| Brief length / format | 104 pages · PDF + executive summary deck · instant delivery |
Understanding the Technology
Phage therapy uses bacteriophages to kill specific bacteria, either as fixed cocktails, as personalised preparations matched to a patient isolate, or as engineered phages and phage-derived proteins.
Selection depends on testing the bacterial isolate against a phage library, and production requires purification to biologic standards.
Delivery is intravenous, inhaled or topical, depending on the infection.
Uses are bloodstream infections, diabetic foot ulcers, respiratory infections in cystic fibrosis and eye and urinary infections.
The limits are strain specificity, manufacturing consistency, unclear approval pathways and developer cash. The period turns on whether pivotal trials show benefit over antibiotics.
Market Outlook
The phage therapy market, covering clinical-stage phage therapeutics, compassionate use programmes, phage production and testing services for resistant bacterial infections, is valued at USD 0.1–0.2 billion in 2026 and is projected to reach USD 2.33–4.66 billion by 2038, at a CAGR of 30%.
The 2026 base rests on clinical-stage programmes funded by grants and strategic investors, compassionate use programmes and phage production and testing services. Growth then follows pivotal trial results, first approvals and wider hospital programmes.
The forecast is sensitive to trial outcomes, developer financing and regulatory pathways. Regionally, North America leads on trials and defense funding, Europe on hospital and academic programmes, and Asia-Pacific on development in China and Australia.
Scenarios
The base case assumes the lead phase 3 trial starts by 2027 and at least one product is approved by 2032, giving the inflection in 2034. An accelerated case assumes a positive phase 3 result and several partnerships, bringing the inflection to 2031 and lifting the 2038 value to the top of the range. A delayed case assumes financing failures and trial setbacks, holding growth at the bottom of the range.
Factors Behind Growth
Growth drivers
- Antimicrobial resistance burden.
- First pivotal trials.
- Government and defense funding.
- Engineered and precision phage approaches.
Enablers
- Qualified Infectious Disease Product incentives.
- Compassionate use frameworks.
- Academic phage banks and hospital programmes.
- Partnerships with larger pharma companies.
Restraints and barriers
- Small developers with limited cash.
- Strain specificity and trial design.
- Manufacturing standards.
- Unclear approval pathways.
The Forces at Play
The direction of phage therapy is set by the need for treatments for resistant infections, regulatory pathways for adaptable biologics, genomics, engineering and automation, partnering among hospitals, biotechnology companies and governments, and funding and manufacturing cost.
Adoption Outlook
How the shift is likely to unfold across three time horizons.
Phase 3 of the lead programme starts if funded, and other phase 2 trials report.
The first phage products reach regulatory decisions and developers consolidate.
Phage therapy is a standard option for resistant infections.
Latest Strategic Developments
| Date | Development | Type | Significance |
|---|---|---|---|
| Mar 2024 | Armata Pharmaceuticals secures a USD 35 million credit facility from Innoviva at 14.0% interest | Financing | Funds the development of AP-SA02 through the largest shareholder |
| Jan 2026 | Armata Pharmaceuticals reports that the FDA reviewed its End-of-Phase 2 submission for AP-SA02 and made recommendations for a phase 3 trial | Regulatory | Defines the route to the first pivotal phage trial for bacteremia |
| Jan 2026 | Armata Pharmaceuticals amends its credit agreements with Innoviva and extends debt maturities to 1 June 2027 | Financing | Extends runway ahead of the planned phase 3 start |
| Mar 2026 | Armata Pharmaceuticals reports cash of USD 14.1 million at the end of 2025 and an auditor paragraph on going concern | Financing | Shows the funding need for a pivotal trial |
| Apr 2026 | Labiotech reports that AP-SA02 holds Qualified Infectious Disease Product designation and that the TP-102 phase 2b trial of TechnoPhage in diabetic foot ulcers showed safety and tolerability | Clinical | Adds regulatory incentives and a second phase 2 result |
Key Players & Competitive Landscape
The key participants in phage therapy include Armata Pharmaceuticals, Inc., Locus Biosciences, Inc., BiomX Inc., TechnoPhage, S.A., Intralytix, Inc., SNIPR Biome ApS, Eligo Bioscience SAS, Phico Therapeutics Ltd, Micreos B.V., Phagelux, Inc., Phagos SAS, Fixed Phage Limited, BioNTech SE, Innoviva, Inc., Viatris Inc., GSK plc, Shionogi & Co., Ltd., Lonza Group Ltd, Charles River Laboratories International, Inc., Pfizer Inc., CARB-X, Wellcome Trust, Gates Foundation, University of California San Diego, Mayo Clinic, Eliava Institute, Hirszfeld Institute of Immunology and Experimental Therapy, Queen Astrid Military Hospital, Monash University, U.S. Department of Defense, Biomedical Advanced Research and Development Authority, National Institutes of Health, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, National Medical Products Administration, Pharmaceuticals and Medical Devices Agency, Infectious Diseases Society of America, European Society of Clinical Microbiology and Infectious Diseases, World Health Organization, Biotechnology Innovation Organization and AMR Industry Alliance.
The brief profiles representative participants in each archetype and assesses which are positioned to lead as phage therapy matures.
Armata Pharmaceuticals leads on the most advanced programme, Locus Biosciences, BiomX, TechnoPhage, Intralytix and SNIPR Biome lead on other clinical and engineered programmes, and Innoviva and Viatris are the main strategic backers. Competitive intensity is low in 2026 and rises as pivotal results arrive.
| Archetype | Representative players | Position in 2026 | Outlook to 2038 |
|---|---|---|---|
| Phage therapy developers | Armata Pharmaceuticals, Locus Biosciences, BiomX, TechnoPhage, Intralytix, SNIPR Biome, Eligo Bioscience, Phico Therapeutics, Micreos, Phagelux, Phagos, Fixed Phage, BioNTech | Phage cocktails, engineered phages and endolysins | Develop products and run trials |
| Pharma, investors and strategic partners | Innoviva, Viatris, GSK, Shionogi, Pfizer | Funding, licensing and partnerships | Fund programmes and license candidates |
| Manufacturers and testing providers | Lonza, Charles River Laboratories | Biologic manufacturing and testing | Supply manufacturing and quality testing |
| Hospitals, universities and funders | CARB-X, Wellcome Trust, Gates Foundation, University of California San Diego, Mayo Clinic, Eliava Institute, Hirszfeld Institute, Queen Astrid Military Hospital, Monash University | Compassionate use, phage banks and grants | Treat patients, hold phage libraries and fund research |
| Government agencies and regulators | U.S. Department of Defense, Biomedical Advanced Research and Development Authority, National Institutes of Health, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, National Medical Products Administration, Pharmaceuticals and Medical Devices Agency | Funding, review and approval | Fund development and review products |
| Societies and industry bodies | Infectious Diseases Society of America, European Society of Clinical Microbiology and Infectious Diseases, World Health Organization, Biotechnology Innovation Organization, AMR Industry Alliance | Guidelines and advocacy | Set clinical guidance and policy positions |
Where value migrates.
In 2026 value sits with developers that have clinical-stage assets and strategic backers, because trial funding decides who survives. By 2032 it moves toward owners of approved phage products, because approvals carry pricing and exclusivity. By 2038 it settles in precision and engineered phage platforms. Margins hold for developers with exclusivity and funded manufacturing and narrow for those that depend on grant funding.
Who Will Win — and Why
The archetypes best positioned to capture value as the shift matures.
Firms with phase 3 data on a defined product.
Firms that can supply phage products at biologic standards.
Firms that back developers and hold rights to later products.
Regulatory Landscape
| Jurisdiction | Milestone | Indicative timing | Effect on adoption |
|---|---|---|---|
| FDA review of phage products | Biologic review of phage products by the Center for Biologics Evaluation and Research | In force | Defines trial requirements and manufacturing expectations |
| Qualified Infectious Disease Product designation | US incentive that adds market exclusivity for antibacterial products | In force | Adds five years of exclusivity after approval |
| EU and national pathways for phage therapy | Hospital exemption and compassionate use rules in Europe | Emerging | Allow personalised use outside trials |
| Defense and public health funding | Government awards for antibacterial development | In force | Fund early clinical programmes |
| Manufacturing and quality requirements | Purity and stability standards for biologics | In force | Raise the cost of scaling phage production |
Investment Signals
The signals converge on a defined first pivotal programme with fragile financing. FDA recommendations for a phase 3 trial, a USD 26.2 million Department of Defense award and a Qualified Infectious Disease Product designation support growth, while developer cash of USD 14.1 million at the lead company, strain specificity and unclear pathways limit the pace.
Structural limits show where progress could slow: small developers with limited cash, strain specificity and trial design, manufacturing standards, and unclear approval pathways. The brief therefore tracks four indicators: pivotal trial starts and readouts, financing and partnerships, first regulatory decisions, and hospital phage programmes.
Bloodstream and device infections first, then chronic wounds and respiratory infections, then personalised and engineered approaches are the expected order of adoption.
Questions This Brief Answers
Strategic Implications
- Phage therapy developers: secure funding for pivotal trials, design trials that handle strain specificity and build manufacturing.
- Hospitals and clinicians: build isolate testing and access programmes and join trials.
- Pharma and defense buyers: decide which programmes to back and set supply plans.
- Policy makers and regulators: clarify pathways for adaptable phage products and expand incentives.
- Investors: treat pivotal trial results, financing, partnerships and first approvals as the leading indicators.
"Phage therapy has a defined route to a pivotal trial for the first time. Whether anyone can pay for that trial is the more pressing question."
Table of Contents
Access & Licensing
A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.
every brief